Auris Medical Holding Ltd (NASDAQ:EARS) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 163,300 shares, a decrease of 5.9% from the July 31st total of 173,600 shares. Based on an average trading volume of 186,200 shares, the short-interest ratio is currently 0.9 days. Currently, 10.4% of the company’s stock are sold short.
Separately, Zacks Investment Research downgraded Auris Medical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 22nd.
Shares of EARS stock traded up $0.10 during midday trading on Friday, reaching $3.02. 672,788 shares of the stock were exchanged, compared to its average volume of 98,118. Auris Medical has a 1 year low of $2.41 and a 1 year high of $39.40. The company’s 50 day moving average is $2.75 and its two-hundred day moving average is $2.10.
An institutional investor recently bought a new position in Auris Medical stock. Jane Street Group LLC bought a new position in shares of Auris Medical Holding Ltd (NASDAQ:EARS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,934 shares of the biotechnology company’s stock, valued at approximately $30,000. Jane Street Group LLC owned 0.58% of Auris Medical as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 10.25% of the company’s stock.
Auris Medical Company Profile
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Featured Story: Day Trading
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.